Our Story

A New Class of Company

Revalia Bio was founded at the intersection of transplant science, data infrastructure, and drug development to solve one of medicine's most pressing failures.

Revalia Bio emerged from Yale's transplant research community, where co-founders Greg Tietjen and Jenna DiRito recognized that the infrastructure for ex vivo organ research — the ability to keep donated organs viable for research outside the body — could be transformed into a systematic platform for human drug testing.

Today, Revalia operates a 8,000 sq ft facility in New Haven, CT and maintains partnerships with transplant centers across the country. With a $26.7M ARPA-H contract and backing from leading life sciences investors, we are building the infrastructure that will transform how drugs are developed for generations to come.

Biophysicist and Revalia Bio Co-Founder Greg Tietjen worked in a lab at Yale with his Co-Founder Jenna DiRito for 11 years on organ perfusion. After learning that many donated organs could not be used for transplant, the pair were committed to finding a purpose for these organs. Revalia was born from this mission to use non-transplantable organs to accelerate research. Greg and Jenna founded the company on the premise of scalable human biological data in 2023, and we have proudly been revenue-generating since day one. As one of the first organizations to work in this space, we have attracted world-class experts to join our mission. Our team includes a transplant surgeon, researchers from Brown and Johnson & Johnson, as well as developers from Google and Amazon. We were recently awarded an ARPA-H Contract (up to $26.7 Million) to advance drug development with the Human Data Stack.